

Avanti Polar Lipids, Inc. 700 Industrial Park Drive, Alabaster, AL 35007, USA • (800) 227-0651 • (205) 663-2494
 • Fax(800) 229-1004 • (205) 663-0756 • E-mail Orders: orders@avantilipids.com • E-mail Inquiries: info@avantilipids.com
 • E-mail Technical Questions: technical@avantilipids.com • Visit www.avantilipids.com

1. PRODUCT AND COMPANY IDENTIFICATION

1.1 Product identifiers

Product name : Dox-NP[®] (5mL vial)

Product Number : 300115S

Brand : AVANTI

1.2 Relevant identified uses of the substance or mixture and uses advised against

Identified uses : Laboratory chemicals, Synthesis of substances

1.3 Details of the supplier of the safety data sheet

Company : Avanti Polar Lipids, INC
 700 Industrial Park Drive
 Alabaster, AL 35007
 United States of America

Telephone : (205) 663-2494

Fax : (205) 663-0756

1.4 Emergency telephone number

Emergency Phone # : +1 703-741-5970 / 1800-424-9300(CHEMTREC)

2. HAZARDS IDENTIFICATION

2.1 Classification of the substance or mixture

GHS Classification in accordance with 29 CFR 1910 (OSHA HCS)

Germ cell mutagenicity (Category 1B), H340

Carcinogenicity (Category 1B), H350

Reproductive toxicity (Category 1B), H360

For the full text of the H-Statements mentioned in this Section, see Section 16.

2.2 GHS Label elements, including precautionary statements

Pictogram



Signal word

Danger

Hazard statement(s)

H340

May cause genetic defects.

H350

May cause cancer.

H360

May damage fertility or the unborn child.

Precautionary statement(s)

P201

Obtain special instructions before use.

P202

Do not handle until all safety precautions have been read and understood.

P280

Wear protective gloves/ protective clothing/ eye protection/ face protection.

P308 + P313

IF exposed or concerned: Get medical advice/ attention.

P405
P501

Store locked up.
Dispose of contents/ container to an approved waste disposal plant.

2.3 Hazards not otherwise classified (HNOC) or not covered by GHS - none

3. COMPOSITION/INFORMATION ON INGREDIENTS

3.2 Mixtures

Hazardous components

Component	Classification	Concentration
Sucrose		
CAS-No. 57-50-1 EC-No. 200-334-9		10 - 20 %
Doxorubicin hydrochloride		
CAS-No. 25316-40-9 EC-No. 246-818-3	Acute Tox. 4; Muta. 1B; Carc. 1B; Repr. 1B; H302, H340, H350, H360	0.1 - 1 %

For the full text of the H-Statements mentioned in this Section, see Section 16.

4. FIRST AID MEASURES

4.1 Description of first aid measures

General advice

Consult a physician. Show this safety data sheet to the doctor in attendance. Move out of dangerous area.

If inhaled

If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.

In case of skin contact

Wash off with soap and plenty of water. Consult a physician.

In case of eye contact

Flush eyes with water as a precaution.

If swallowed

Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.

4.2 Most important symptoms and effects, both acute and delayed

The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11

4.3 Indication of any immediate medical attention and special treatment needed

No data available

5. FIREFIGHTING MEASURES

5.1 Extinguishing media

Suitable extinguishing media

Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.

5.2 Special hazards arising from the substance or mixture

No data available

5.3 Advice for firefighters

Wear self-contained breathing apparatus for firefighting if necessary.

5.4 Further information

No data available

6. ACCIDENTAL RELEASE MEASURES

6.1 Personal precautions, protective equipment and emergency procedures

Use personal protective equipment. Avoid breathing vapours, mist or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.

For personal protection see section 8.

6.2 Environmental precautions

Prevent further leakage or spillage if safe to do so. Do not let product enter drains.

6.3 Methods and materials for containment and cleaning up

Soak up with inert absorbent material and dispose of as hazardous waste. Keep in suitable, closed containers for disposal.

6.4 Reference to other sections

For disposal see section 13.

7. HANDLING AND STORAGE

7.1 Precautions for safe handling

Avoid inhalation of vapour or mist.

For precautions see section 2.2.

7.2 Conditions for safe storage, including any incompatibilities

Keep container tightly closed in a dry and well-ventilated place. Containers which are opened must be carefully resealed and kept upright to prevent leakage.

Recommended storage temperature -20 °C

Storage class (TRGS 510): 6.1D: Non-combustible, acute toxic Cat.3 / toxic hazardous materials or hazardous materials causing chronic effects

7.3 Specific end use(s)

Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1 Control parameters

Components with workplace control parameters

Component	CAS-No.	Value	Control parameters	Basis
Sucrose	57-50-1	TWA	10 mg/m ³	USA. ACGIH Threshold Limit Values (TLV)
	Remarks	Dental erosion Not classifiable as a human carcinogen		
		TWA	10.000000 mg/m ³	USA. ACGIH Threshold Limit Values (TLV)
		Dental erosion Not classifiable as a human carcinogen		

		TWA	15.000000 mg/m3	USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants
		TWA	5.000000 mg/m3	USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants
		TWA	5.000000 mg/m3	USA. NIOSH Recommended Exposure Limits
		TWA	10.000000 mg/m3	USA. NIOSH Recommended Exposure Limits
		PEL	10 mg/m3	California permissible exposure limits for chemical contaminants (Title 8, Article 107)
		PEL	5 mg/m3	California permissible exposure limits for chemical contaminants (Title 8, Article 107)

Hazardous components without workplace control parameters

8.2 Exposure controls

Appropriate engineering controls

Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at the end of workday.

Personal protective equipment

Eye/face protection

Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).

Skin protection

Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in accordance with applicable laws and good laboratory practices. Wash and dry hands.

Body Protection

Complete suit protecting against chemicals, The type of protective equipment must be selected according to the concentration and amount of the dangerous substance at the specific workplace.

Respiratory protection

Where risk assessment shows air-purifying respirators are appropriate use a full-face respirator with multi-purpose combination (US) or type ABEK (EN 14387) respirator cartridges as a backup to engineering controls. If the respirator is the sole means of protection, use a full-face supplied air respirator. Use respirators and components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU).

Control of environmental exposure

Prevent further leakage or spillage if safe to do so. Do not let product enter drains.

9. PHYSICAL AND CHEMICAL PROPERTIES

9.1 Information on basic physical and chemical properties

- | | |
|--|-------------------|
| a) Appearance | Form: liquid |
| b) Odour | No data available |
| c) Odour Threshold | No data available |
| d) pH | No data available |
| e) Melting point/freezing point | No data available |
| f) Initial boiling point and boiling range | No data available |
| g) Flash point | No data available |
| h) Evaporation rate | No data available |

- | | |
|---|-------------------|
| i) Flammability (solid, gas) | No data available |
| j) Upper/lower flammability or explosive limits | No data available |
| k) Vapour pressure | No data available |
| l) Vapour density | No data available |
| m) Relative density | No data available |
| n) Water solubility | No data available |
| o) Partition coefficient: n-octanol/water | No data available |
| p) Auto-ignition temperature | No data available |
| q) Decomposition temperature | No data available |
| r) Viscosity | No data available |
| s) Explosive properties | No data available |
| t) Oxidizing properties | No data available |

9.2 Other safety information

No data available

10. STABILITY AND REACTIVITY

10.1 Reactivity

No data available

10.2 Chemical stability

Stable under recommended storage conditions.

10.3 Possibility of hazardous reactions

No data available

10.4 Conditions to avoid

No data available

10.5 Incompatible materials

Strong oxidizing agents

10.6 Hazardous decomposition products

Hazardous decomposition products formed under fire conditions. - Carbon oxides
In the event of fire: see section 5

11. TOXICOLOGICAL INFORMATION

11.1 Information on toxicological effects

Acute toxicity

No data available

Inhalation: No data available

Dermal: No data available

No data available

Skin corrosion/irritation

No data available

Serious eye damage/eye irritation

No data available

Respiratory or skin sensitisation

No data available

Germ cell mutagenicity

No data available

Carcinogenicity

IARC: No component of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

NTP: RAHC - Reasonably anticipated to be a human carcinogen (Doxorubicin hydrochloride)

OSHA: No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

Reproductive toxicity

No data available

No data available

Specific target organ toxicity - single exposure

No data available

Specific target organ toxicity - repeated exposure

No data available

Aspiration hazard

No data available

Additional Information

RTECS: Not available

To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated.

Liver - Irregularities - Based on Human Evidence

Liver - Irregularities - Based on Human Evidence (Doxorubicin hydrochloride)

12. ECOLOGICAL INFORMATION**12.1 Toxicity**

No data available

12.2 Persistence and degradability

No data available

12.3 Bioaccumulative potential

No data available

12.4 Mobility in soil

No data available

12.5 Results of PBT and vPvB assessment

PBT/vPvB assessment not available as chemical safety assessment not required/not conducted

12.6 Other adverse effects

No data available

13. DISPOSAL CONSIDERATIONS**13.1 Waste treatment methods****Product**

Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed professional waste disposal service to dispose of this material. Dissolve or mix the material with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.

Contaminated packaging

Dispose of as unused product.

14. TRANSPORT INFORMATION**DOT (US)**

Not dangerous goods

IMDG

Not dangerous goods

IATA

Not dangerous goods

15. REGULATORY INFORMATION**SARA 302 Components**

This material does not contain any components with a section 302 EHS TPQ.

SARA 313 Components

This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

SARA 311/312 Hazards

Chronic Health Hazard

Massachusetts Right To Know Components

	CAS-No.	Revision Date
Sucrose	57-50-1	1991-07-01

Pennsylvania Right To Know Components

	CAS-No.	Revision Date
Water	7732-18-5	
Sucrose	57-50-1	1991-07-01
Ammonium sulphate	7783-20-2	1993-04-24
Doxorubicin hydrochloride	25316-40-9	2014-10-14

California Prop. 65 Components

	CAS-No.	Revision Date
, which is/are known to the State of California to cause cancer and birth defects or other reproductive harm. For more information go to www.P65Warnings.ca.gov . Doxorubicin hydrochloride	25316-40-9	2008-06-17

16. OTHER INFORMATION

Full text of H-Statements referred to under sections 2 and 3.

Acute Tox.	Acute toxicity
Carc.	Carcinogenicity
H302	Harmful if swallowed.
H340	May cause genetic defects.
H350	May cause cancer.
H360	May damage fertility or the unborn child.
Muta.	Germ cell mutagenicity
Repr.	Reproductive toxicity

Further information

Copyright 2016 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only. The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a guide. The information in this document is based on the present state of our knowledge and is applicable to the product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling or from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

Preparation Information
Sigma-Aldrich Corporation
Product Safety – Americas Region
1-800-521-8956

Version: 5.1

Revision Date: 10/10/2018

Print Date: 09/30/2019